Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|June 1, 2016

BioPharm International

  • BioPharm International-06-01-2016
  • Volume 29
  • Issue 6

Acoustic Separator Streamlines Clarifications

The Cadence Acoustic Separator (CAS) from Pall Life Sciences enables the purification of bioprocesses fluids without the use of primary depth filters or centrifuges.

The Cadence Acoustic Separator (CAS) from Pall Life Sciences enables the purification of bioprocesses fluids without the use of primary depth filters or centrifuges. CAS was developed by FloDesign Sonics and is licensed by Pall. CAS’s acoustic wave separation (AWS) technology applies acoustic forces across a countercurrent flow of bioprocess fluid to generate three-dimensional standing waves that trap cells in their nodes. The cells in the bioprocess fluid will agglomerate and eventually sediment as it loses its buoyancy. 

The CAS does not cause any significant increase in temperature or damage to cells or proteins. The CAS system allows for the reduction of 75% of the filtration area and associated buffer volume requirements. AWS technology is applicable for the clarification of biologic products, including recombinant therapeutic proteins and monoclonal antibodies. In addition, the CAS is a single-use clarification system that enables continuous processing.

Pall Life Sciences
 


Related to this article

The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.